This Marijuana Stock's Expenses Are Soaring

GW Pharmaceuticals Inc. (NASDAQ: GWPH  ) has the richest pipeline of marijuana-derived medicines in development, and that has investors flocking to pick up shares in hopes of benefiting from the rising adoption of such drugs. But a flurry of research trials is also costing the company big bucks, so investors should pay close attention to how quickly it burns through its cash stockpile.

Advancing medical marijuana
GW Pharmaceuticals already markets Sativex, a therapy for multiple sclerosis spasticity that is derived from the marijuana cannabinoid THC.

The drug, which is approved in Europe but not in the U.S., aims to reduce the painful muscle tightness and spasms often experienced by MS patients. Although Sativex has been on the market since 2010, it has failed to make a very big mark in the indication, with sales now totaling roughly $1.7...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.


URL: 
http://www.fool.com/investing/general/2015/05/16/this-marijuana-stocks-expenses-are-soaring.aspx